Trademark: 79365404
Word
DEVELOPICK
Status Date
Tuesday, May 14, 2024
Filing Date
Tuesday, January 31, 2023
40 Custom manufacture of polyclonal antibodies for pharmaceutical use; custom manufacture of biopharmaceuticals; processing of biopharmaceutical materials for others; treatment of biopharmaceutical materials; processing of plant hormones (phytohormones); processing of medicinal materials; processing of pharmaceutical preparations; custom manufacture of pharmaceuticals; processing of pharmaceuticals; custom manufacture of pharmaceutical bispecific antibodies; processing of chemical reagents
42 Advisory services relating to technological research; advisory services relating to scientific analysis; research relating to science; conducting of technical feasibility studies; multiple nucleic acid analysis; multiple nucleic check; analysis of materials; materials testing and evaluation; chemical analysis services for use in the testing of material; molecular analysis; advisory services relating to biotechnology; technical management advisory services relating to biotechnology; biotechnology services; biochemical analysis; advisory services relating to biochemistry; conducting early evaluations in the field of new pharmaceuticals; drug discovery services; design of new products; technical advice relating to safety; pharmaceutical research and development; pharmaceutical products evaluation; clinical research in the field of medicines; services for assessing the efficiency of pharmaceuticals; testing of raw materials; fusion protein analysis; computer programming services in the medical field; computer project management services relating to imaging medical data; medicine research; analysis and evaluation of medical product development; pharmaceutical technology advisory service; pharmaceutical product evaluation; providing information on the testing, inspection and research of medical products; pharmaceutical product evaluation; laboratory services relating to the production of bispecific antibody; bispecific antibody drug development; double antibody reagent research and development; evaluating of clinical tiral progress; clinical research; evaluation of product development; product safety testing; quality assurance consultancy; quality assessment; advisory services relating to chemical reagents; evaluation of chemical syntheses
Mar 21, 2023
Application Filing Receipt Mailed
Nov 2, 2023
Non-Final Action Mailed - Refusal Sent To Ib
Mar 16, 2023
Sn Assigned For Sect 66a Appl From Ib
Mar 17, 2023
New Application Office Supplied Data Entered
Oct 30, 2023
Assigned To Examiner
Nov 1, 2023
Non-Final Action Written
Nov 2, 2023
Refusal Processed By Mpu
Nov 2, 2023
Non-Final Action (Ib Refusal) Prepared For Review
May 14, 2024
Teas Petition To Revive Received
May 14, 2024
Petition To Revive-Granted
May 14, 2024
Teas Petition To Revive Received
May 14, 2024
Teas Response To Office Action Received
May 14, 2024
Notice Of Revival - E-Mailed
Nov 22, 2023
Refusal Processed By Ib
Trademark Alertz updated from USPTO on 2030-01-24
